Perrigo Company plc Selling and Marketing Expense
Perrigo Company plc (PRGO) reported Selling and Marketing Expense of $129.50 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-05
- Perrigo Company plc selling and marketing expense for the quarter ending 2026-06-27 was $129.50M, a 5.13% decline year-over-year.
- Perrigo Company plc selling and marketing expense for the quarter ending 2026-03-28 was $129.70M, a 11.29% decline year-over-year.
- Perrigo Company plc selling and marketing expense for the quarter ending 2025-12-31 was $116.60M, a 0.17% decline year-over-year.
- Perrigo Company plc selling and marketing expense for the quarter ending 2025-09-27 was $127.30M, a 1.62% decline year-over-year.
- Perrigo Company plc selling and marketing expense for fiscal 2025 was $526.50M, a 3.68% decline from fiscal 2024.
- Perrigo Company plc selling and marketing expense for fiscal 2024 was $546.60M, a 14.83% decline from fiscal 2023.
- Perrigo Company plc selling and marketing expense for fiscal 2023 was $641.80M, a 9.75% increase from fiscal 2022.
- Perrigo Company plc selling and marketing expense for fiscal 2022 was $584.80M, a 9.02% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $129.50M 10-Q · filed 2026-08-05 | $259.20M 10-Q · filed 2026-08-05 | $375.80M derived: sum of 3 quarters · filed 2026-08-05 | $503.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $129.70M 10-Q · filed 2026-05-06 | $246.30M derived: sum of 2 quarters · filed 2026-05-06 | $373.60M derived: sum of 3 quarters · filed 2026-05-06 | $510.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $116.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $243.90M derived: sum of 2 quarters · filed 2026-02-26 | $380.40M derived: sum of 3 quarters · filed 2026-08-05 | $526.50M 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $127.30M 10-Q · filed 2025-11-05 | $263.80M derived: sum of 2 quarters · filed 2026-08-05 | $409.90M 10-Q · filed 2025-11-05 | $526.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $136.50M 10-Q · filed 2026-08-05 | $282.70M 10-Q · filed 2026-08-05 | $399.50M derived: sum of 3 quarters · filed 2026-08-05 | $528.90M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $146.20M 10-Q · filed 2026-05-06 | $263.00M derived: sum of 2 quarters · filed 2026-05-06 | $392.40M derived: sum of 3 quarters · filed 2026-05-06 | $542.50M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $116.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $246.20M derived: sum of 2 quarters · filed 2026-02-26 | $396.30M derived: sum of 3 quarters · filed 2026-02-26 | $546.60M 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $129.40M 10-Q · filed 2025-11-05 | $279.50M derived: sum of 2 quarters · filed 2025-11-05 | $429.80M 10-Q · filed 2025-11-05 | $582.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $150.10M 10-Q · filed 2025-08-06 | $300.40M 10-Q · filed 2025-08-06 | $453.00M derived: sum of 3 quarters · filed 2026-02-26 | $603.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $150.30M 10-Q · filed 2025-05-07 | $302.90M derived: sum of 2 quarters · filed 2026-02-26 | $453.10M derived: sum of 3 quarters · filed 2026-02-26 | $624.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $152.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $302.80M derived: sum of 2 quarters · filed 2026-02-26 | $473.90M derived: sum of 3 quarters · filed 2026-02-26 | $641.80M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $150.20M 10-Q · filed 2024-11-06 | $321.30M derived: sum of 2 quarters · filed 2024-11-06 | $489.20M 10-Q · filed 2024-11-06 | $643.00M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $171.10M 10-Q · filed 2024-08-02 | $339.00M 10-Q · filed 2024-08-02 | $492.80M derived: sum of 3 quarters · filed 2025-02-28 | $637.30M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $167.90M 10-Q · filed 2024-05-07 | $321.70M derived: sum of 2 quarters · filed 2025-02-28 | $466.20M derived: sum of 3 quarters · filed 2025-02-28 | $617.00M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $153.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $298.30M derived: sum of 2 quarters · filed 2025-02-28 | $449.10M derived: sum of 3 quarters · filed 2025-02-28 | $584.80M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $144.50M 10-Q · filed 2023-11-07 | $295.30M derived: sum of 2 quarters · filed 2023-11-07 | $431.00M 10-Q · filed 2023-11-07 | $562.30M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $150.80M 10-Q · filed 2023-08-08 | $286.40M 10-Q · filed 2023-08-08 | $417.80M derived: sum of 3 quarters · filed 2024-02-27 | $547.50M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $135.60M 10-Q · filed 2023-05-09 | $267.00M derived: sum of 2 quarters · filed 2024-02-27 | $396.70M derived: sum of 3 quarters · filed 2024-02-27 | $536.50M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $131.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $261.10M derived: sum of 2 quarters · filed 2024-02-27 | $400.90M derived: sum of 3 quarters · filed 2024-02-27 | $536.40M 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $129.70M 10-Q · filed 2022-11-08 | $269.50M derived: sum of 2 quarters · filed 2022-11-08 | $405.00M 10-Q · filed 2022-11-08 | $561.50M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | $139.80M 10-Q · filed 2022-08-09 | $275.20M 10-Q · filed 2022-08-09 | $431.80M derived: sum of 3 quarters · filed 2023-02-28 | $561.90M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $135.50M 10-Q · filed 2022-05-11 | $292.00M derived: sum of 2 quarters · filed 2023-02-28 | $422.10M derived: sum of 3 quarters · filed 2023-02-28 | $541.40M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $156.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $286.60M derived: sum of 2 quarters · filed 2023-02-28 | $405.90M derived: sum of 3 quarters · filed 2023-02-28 | $545.50M 10-K · filed 2023-02-28 | $579.10M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $130.10M 10-Q · filed 2021-11-12 | $138.50M 10-Q · filed 2020-11-05 | $249.40M derived: sum of 2 quarters · filed 2021-11-12 | $389.00M 10-Q · filed 2021-11-12 | $413.90M 10-Q · filed 2020-11-05 | $504.90M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-27 | $119.30M 10-Q · filed 2021-08-11 | $127.60M 10-Q · filed 2020-08-05 | $258.90M 10-Q · filed 2021-08-11 | $275.30M 10-Q · filed 2020-08-05 | $374.80M derived: sum of 3 quarters · filed 2022-03-01 | $508.90M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-28 | $139.60M 10-Q · filed 2021-05-12 | $147.70M 10-Q · filed 2020-05-05 | $255.50M derived: sum of 2 quarters · filed 2022-03-01 | $389.60M derived: sum of 3 quarters · filed 2022-03-01 | $529.70M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $115.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $250.00M derived: sum of 2 quarters · filed 2022-03-01 | $390.10M derived: sum of 3 quarters · filed 2022-03-01 | $538.70M 10-K · filed 2022-03-01 | $567.00M 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $134.10M 10-Q · filed 2020-11-05 | $274.20M derived: sum of 2 quarters · filed 2020-11-05 | $422.80M 10-Q · filed 2020-11-05 | $567.30M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $140.10M 10-Q · filed 2020-08-05 | $288.70M 10-Q · filed 2020-08-05 | $433.20M derived: sum of 3 quarters · filed 2021-03-01 | $567.90M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $148.60M 10-Q · filed 2020-05-05 | $293.10M derived: sum of 2 quarters · filed 2021-03-01 | $427.80M derived: sum of 3 quarters · filed 2021-03-01 | $583.00M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $144.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $279.20M derived: sum of 2 quarters · filed 2021-03-01 | $434.40M derived: sum of 3 quarters · filed 2021-03-01 | $595.70M 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $134.70M 10-Q · filed 2019-11-06 | $289.90M derived: sum of 2 quarters · filed 2019-11-06 | $451.20M 10-Q · filed 2019-11-06 | $595.50M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $155.20M 10-Q · filed 2019-08-08 | $316.50M 10-Q · filed 2019-08-08 | $460.80M derived: sum of 3 quarters · filed 2020-02-27 | $604.30M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $161.30M 10-Q · filed 2019-05-09 | $305.60M derived: sum of 2 quarters · filed 2020-02-27 | $449.10M derived: sum of 3 quarters · filed 2020-02-27 | $604.70M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $144.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $287.80M derived: sum of 2 quarters · filed 2020-02-27 | $443.40M derived: sum of 3 quarters · filed 2020-02-27 | $598.40M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $143.50M 10-Q · filed 2018-11-08 | $299.10M derived: sum of 2 quarters · filed 2018-11-08 | $454.10M 10-Q · filed 2018-11-08 | $612.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-07-01 | $155.60M 10-Q · filed 2018-08-09 | $310.60M 10-Q · filed 2018-08-09 | $468.70M derived: sum of 3 quarters · filed 2019-02-27 | $623.30M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-04-01 | $155.00M 10-Q · filed 2018-05-08 | $313.10M derived: sum of 2 quarters · filed 2019-02-27 | $467.70M derived: sum of 3 quarters · filed 2019-02-27 | $639.30M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $158.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $312.70M derived: sum of 2 quarters · filed 2019-02-27 | $484.30M derived: sum of 3 quarters · filed 2019-02-27 | $665.00M 10-K · filed 2019-02-27 | ||||
| 2016-10-01 | $154.60M 10-Q · filed 2017-11-09 | $326.20M derived: sum of 2 quarters · filed 2017-11-09 | $506.90M 10-Q · filed 2017-11-09 | $665.00M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-07-02 | $171.60M 10-Q · filed 2017-08-10 | $352.40M 10-Q · filed 2017-08-10 | $510.40M derived: sum of 3 quarters · filed 2018-03-01 | $678.30M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-04-02 | $180.80M 10-Q · filed 2017-05-30 | $338.80M derived: sum of 2 quarters · filed 2018-03-01 | $506.70M derived: sum of 3 quarters · filed 2018-03-01 | $681.60M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $158.00M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $325.90M 10-K · filed 2018-03-01 | $500.80M derived: sum of 3 quarters · filed 2018-03-01 | $549.60M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-09-26 | $167.90M 10-Q/A · filed 2017-05-23 | $342.80M derived: sum of 2 quarters · filed 2017-05-23 | $391.60M 10-Q/A · filed 2017-05-23 | $436.50M derived: sum of 4 quarters · filed 2017-05-23 | ||||
| 2015-06-27 | $174.90M 10-Q/A · filed 2017-05-22 | $223.70M 10-Q/A · filed 2017-05-22 | $268.60M derived: sum of 3 quarters · filed 2017-05-22 | $319.00M 10-K · filed 2018-03-01 | ||||
| 2015-03-28 | $48.80M 10-Q/A · filed 2017-05-22 | $93.70M derived: sum of 2 quarters · filed 2017-05-22 | $144.00M 10-Q · filed 2015-04-29 | $202.70M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-12-27 | $44.90M 10-Q · filed 2015-02-05 | $95.30M 10-K · filed 2018-03-01 | $153.90M derived: sum of 3 quarters · filed 2017-05-22 | $206.40M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-09-27 | $50.40M 10-Q · filed 2015-11-02 | $109.00M derived: sum of 2 quarters · filed 2017-05-22 | $161.50M derived: sum of 3 quarters · filed 2017-05-22 | $208.80M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $58.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $111.10M derived: sum of 2 quarters · filed 2017-05-22 | $158.40M derived: sum of 3 quarters · filed 2017-05-22 | $208.60M 10-K · filed 2017-05-22 | ||||
| 2014-03-29 | $52.50M 10-Q · filed 2015-04-29 | $99.80M derived: sum of 2 quarters · filed 2015-04-29 | $150.00M 10-Q · filed 2015-04-29 | $206.50M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-28 | $47.30M 10-Q · filed 2015-02-05 | $97.60M 10-Q · filed 2015-02-05 | $154.00M derived: sum of 3 quarters · filed 2016-02-25 | $203.10M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-09-28 | $50.20M 8-K · filed 2014-11-20 | $106.70M derived: sum of 2 quarters · filed 2016-02-25 | $155.80M derived: sum of 3 quarters · filed 2016-02-25 | $198.90M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-06-29 | $56.50M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $105.60M derived: sum of 2 quarters · filed 2016-02-25 | $148.70M derived: sum of 3 quarters · filed 2016-02-25 | $186.10M 10-KT · filed 2016-02-25 | ||||
| 2013-03-30 | $49.10M 10-Q · filed 2014-05-07 | $92.20M derived: sum of 2 quarters · filed 2014-05-07 | $129.60M 10-Q · filed 2014-05-07 | |||||
| 2012-12-29 | $43.10M 10-Q · filed 2014-02-06 | $80.50M 10-Q · filed 2014-02-06 | ||||||
| 2012-06-30 | $148.30M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |